ETF Holdings Breakdown of RXRX

RXRX institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-09-30	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	224,257	USD 1,094,374
2025-09-30	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	97,069	USD 473,697
2025-09-30	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	486,490	USD 2,374,071
2025-09-30	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	242,635	USD 1,184,059
2025-09-30	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	242,635 0.6%	USD 1,184,059 0.0%
2025-09-30	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	2,123	USD 10,360
Total =		1,295,209	USD 6,320,620

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with RXRX

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Bought by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 9.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 30,864 shares of the company’s stock after acquiring an additional 2,587 shares during […] - 2025-08-15 04:46:57

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) have earned an average rating of “Hold” from the six analysts that are presently covering the stock, MarketBeat reports. Four equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price […] - 2025-08-13 02:28:44

Blair William & Co. IL Raises Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Blair William & Co. IL lifted its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 854.2% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 114,500 shares of the company’s stock after buying an additional 102,500 shares during the quarter. […] - 2025-08-11 05:52:57

Pre-Market Most Active for Aug 5, 2025 : OPEN, AIP, TSLL, PFE, RXRX, PLTR, SQQQ, HIMS, BBAI, NIO, FIG, JOBY

The NASDAQ 100 Pre-Market Indicator is up 64.21 to 23,252.82. The total Pre-Market volume is currently 183,775,922 shares traded.The following are the most active stocks for the pre-market session: Opendoor Technologies Inc (OPEN) is +0.0191 at $2.48, with 7,136,575 shares trade - 2025-08-05 09:29:57

Cerity Partners LLC Invests $332,000 in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Cerity Partners LLC purchased a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) during the first quarter, Holdings Channel reports. The fund purchased 62,691 shares of the company’s stock, valued at approximately $332,000. A number of other institutional investors have also recently made changes to their positions in the stock. GAMMA Investing LLC […] - 2025-07-28 04:28:49

Pre-Market Most Active for Jul 22, 2025 : OPEN, TSLL, REPL, SQQQ, OSCR, NVDA, QS, RXRX, BBAI, JOBY, NIO, CVX

The NASDAQ 100 Pre-Market Indicator is down -5.34 to 23,174.72. The total Pre-Market volume is currently 168,215,532 shares traded.The following are the most active stocks for the pre-market session: Opendoor Technologies Inc (OPEN) is +0.62 at $3.83, with 67,855,698 shares trad - 2025-07-22 09:29:55

Stratos Wealth Partners LTD. Has $63,000 Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Stratos Wealth Partners LTD. decreased its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 27.7% during the 1st quarter, Holdings Channel reports. The firm owned 11,974 shares of the company’s stock after selling 4,579 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in Recursion Pharmaceuticals were worth $63,000 at the end of […] - 2025-07-18 04:34:52

D.A. Davidson & CO. Raises Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

D.A. Davidson & CO. boosted its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 571.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 107,432 shares of the company’s stock after acquiring an additional 91,438 […] - 2025-07-11 05:26:53

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Bought by GAMMA Investing LLC

GAMMA Investing LLC grew its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 39.0% in the first quarter, according to its most recent filing with the SEC. The fund owned 7,224 shares of the company’s stock after acquiring an additional 2,026 shares during the period. GAMMA Investing LLC’s holdings in Recursion […] - 2025-07-11 04:45:22

Wealth Enhancement Advisory Services LLC Raises Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Wealth Enhancement Advisory Services LLC raised its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 27.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 24,230 shares of the company’s stock after buying an additional 5,278 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Recursion Pharmaceuticals were worth $128,000 as […] - 2025-07-11 04:08:55

Recursion Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) saw unusually large options trading activity on Wednesday. Stock investors bought 29,275 call options on the company. This is an increase of approximately 43% compared to the average daily volume of 20,478 call options. Recursion Pharmaceuticals Price Performance NASDAQ RXRX opened at $5.72 on Friday. The company […] - 2025-07-11 02:18:48

Recursion Pharmaceuticals: The AI Drug Discovery Play

Recursion Pharmaceuticals (NASDAQ:RXRX) has seen significant share price volatility in 2025, dropping 27% year-to-date and trading over 55% below its 52-week high of $12. Despite this underperformance, the clinical-stage TechBio company continues to garner attention for its innov - 2025-07-08 23:56:11

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $7.00 Average Price Target from Analysts

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) have been given a consensus recommendation of “Hold” by the six research firms that are presently covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month […] - 2025-06-27 02:10:58

Morgan Stanley Has Lowered Expectations for Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its target price cut by analysts at Morgan Stanley from $8.00 to $5.00 in a report released on Monday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s target price indicates a potential upside of 3.31% from the stock’s previous close. Several […] - 2025-06-18 02:50:50

Azzad Asset Management Inc. ADV Raises Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Azzad Asset Management Inc. ADV boosted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 21.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,811 shares of the company’s stock after buying an additional 2,982 shares during the period. […] - 2025-06-16 05:54:48

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Integrated Advisors Network LLC

Integrated Advisors Network LLC boosted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 17.1% during the 1st quarter, Holdings Channel reports. The fund owned 20,603 shares of the company’s stock after acquiring an additional 3,015 shares during the quarter. Integrated Advisors Network LLC’s holdings in Recursion Pharmaceuticals were worth $109,000 as of […] - 2025-06-16 05:05:20

California State Teachers Retirement System Acquires 54,449 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

California State Teachers Retirement System boosted its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 30.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 231,535 shares of the company’s stock after acquiring an additional 54,449 shares during the quarter. […] - 2025-06-09 04:43:00

Squarepoint Ops LLC Takes Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Squarepoint Ops LLC bought a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 80,421 shares of the company’s stock, valued at approximately $544,000. A number of other institutional investors also […] - 2025-06-04 05:48:48

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Rating of “Hold” from Analysts

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) have earned a consensus rating of “Hold” from the six research firms that are covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective […] - 2025-05-30 02:10:57

Two Sigma Advisers LP Has $3.05 Million Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Two Sigma Advisers LP trimmed its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 7.8% in the 4th quarter, Holdings Channel.com reports. The fund owned 451,745 shares of the company’s stock after selling 38,155 shares during the quarter. Two Sigma Advisers LP’s holdings in Recursion Pharmaceuticals were worth $3,054,000 as of […] - 2025-05-27 05:57:01

Man Group plc Makes New $479,000 Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Man Group plc bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) in the 4th quarter, HoldingsChannel reports. The fund bought 70,802 shares of the company’s stock, valued at approximately $479,000. Several other hedge funds also recently bought and sold shares of RXRX. Private Trust Co. NA purchased a new […] - 2025-05-27 04:59:05

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Cresset Asset Management LLC

Cresset Asset Management LLC lessened its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 64.6% during the fourth quarter, HoldingsChannel reports. The fund owned 25,029 shares of the company’s stock after selling 45,663 shares during the period. Cresset Asset Management LLC’s holdings in Recursion Pharmaceuticals were worth $169,000 at the end […] - 2025-05-19 05:02:51

Price T Rowe Associates Inc. MD Raises Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Price T Rowe Associates Inc. MD raised its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 17.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 131,990 shares of the company’s stock after acquiring an additional […] - 2025-05-12 05:10:49

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.4% After Earnings Miss

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report)’s stock price fell 5.4% on Tuesday following a weaker than expected earnings announcement. The stock traded as low as $4.45 and last traded at $4.51. 7,052,787 shares were traded during trading, a decline of 44% from the average session volume of 12,553,666 shares. The stock had previously […] - 2025-05-08 02:42:51

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $8.20 Consensus Price Target from Analysts

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) have received a consensus recommendation of “Hold” from the six brokerages that are currently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price target […] - 2025-05-08 02:04:58

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 9.6% on Disappointing Earnings

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) shares dropped 9.6% on Monday following a dissappointing earnings announcement. The company traded as low as $5.23 and last traded at $5.16. Approximately 9,031,494 shares were traded during trading, a decline of 28% from the average daily volume of 12,478,559 shares. The stock had previously closed at […] - 2025-05-07 02:54:42

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down on Disappointing Earnings

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) gapped down prior to trading on Monday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $5.70, but opened at $5.49. Recursion Pharmaceuticals shares last traded at $5.33, with a volume of 5,427,114 shares. The company reported ($0.50) earnings per share […] - 2025-05-06 02:10:57

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Bought by Mariner LLC

Mariner LLC boosted its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 32.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 111,063 shares of the company’s stock after buying an additional 27,499 shares during the quarter. […] - 2025-04-29 04:56:57

Barclays PLC Has $4.28 Million Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Barclays PLC trimmed its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 9.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 633,125 shares of the company’s stock after selling 64,307 shares during the period. Barclays PLC’s holdings […] - 2025-04-28 04:59:05

JPMorgan Chase & Co. Sells 119,024 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

JPMorgan Chase & Co. trimmed its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 10.1% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 1,057,167 shares of the company’s stock after selling 119,024 shares during the period. JPMorgan Chase & Co.’s holdings in Recursion Pharmaceuticals were worth $7,146,000 at the end of […] - 2025-04-17 04:27:22

Back to Listing

Disclaimer